Advertisement
Research Article

Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site

  • Barna Dey,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Krisha Svehla,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Ling Xu,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Dianne Wycuff,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Tongqing Zhou,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Gerald Voss,

    Affiliation: GlaxoSmithKline Biologicals, Rixensart, Belgium

    X
  • Adhuna Phogat,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Bimal K. Chakrabarti,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Yuxing Li,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • George Shaw,

    Affiliation: University of Alabama Birmingham, Birmingham, Alabama, United States of America

    X
  • Peter D. Kwong,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Gary J. Nabel,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • John R. Mascola,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Richard T. Wyatt mail

    richardwyatt@nih.gov

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Published: May 29, 2009
  • DOI: 10.1371/journal.ppat.1000445

About the Authors

Barna Dey, Krisha Svehla, Ling Xu, Dianne Wycuff, Tongqing Zhou, Adhuna Phogat, Bimal K. Chakrabarti, Yuxing Li, Peter D. Kwong, Gary J. Nabel, John R. Mascola, Richard T. Wyatt
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
Gerald Voss
GlaxoSmithKline Biologicals, Rixensart, Belgium
George Shaw
University of Alabama Birmingham, Birmingham, Alabama, United States of America

Corresponding Author

Email: richardwyatt@nih.gov

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: BD TZ PDK GJN JRM RTW. Performed the experiments: BD KS LX. Analyzed the data: BD KS GJN JRM RTW. Contributed reagents/materials/analysis tools: LX DW GV AP BKC YL GS. Wrote the paper: BD PDK RTW.